期刊文献+

阿托伐他汀钙治疗高脂血症合并高尿酸血症的临床研究 被引量:5

Clinical Study on Atorvastatin Calcium in the Treatment of Hyperlipidemia with Hyperuricemia
下载PDF
导出
摘要 目的比较观察阿托伐他汀钙治疗高脂血症合并高尿酸血症的临床疗效。方法 60例高脂血症合并高尿酸血症,随机分为两组:阿托伐他汀钙组30例,口服阿托伐他汀钙20 mg;辛伐他汀组30例,口服辛伐他汀20 mg;均每晚睡前顿服1次,疗程8周。对比两组治疗前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)和血尿酸(BUA)的变化。结果两组治疗后TC、LDL-C、TG均有降低和HDL-C升高(P<0.05);但治疗后阿托伐他汀钙组血尿酸水平明显下降(P<0.05),而辛伐他汀组下降不明显(P>0.05);两组比较差异有统计学意义(P<0.05)。结论阿托伐他汀钙有较好的降脂外,还有降低血尿酸作用。所以对高脂血症合并高尿酸血症患者应首选阿托伐他汀钙。 Objective To compare the clinical effects of atorvastatin calcium in the treatment of hyperlipidemia with hyperuricemia.Methods 60 patients with hyperlipidemia and hyperuricemia were randomly divided into two groups: 30 cases of atorvastatin calcium group,who took orally atorvastatin calcium 20 mg;30 cases of simvastatin group,who took orally simvastatin 20 mg;and all took pills at a draught for one time before going to bed for 8 weeks,to compare the changes of total cholesterol(TC),triglyceride(TG),low density lipopro-tein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C) and blood uric acid(BUA) before and after treatment.Results After treatment,TC,LDL-C,TG reduced and HDL-C increased in both-groups(P 0.05),but the atorvastatin calcium group's blood uric acid levels also decreased after treatment(P 0.05),with no significant decline in the simvastatin group(P 0.05).The comparison had significant difference between the two groups(P 0.05).Conclusion Atorvastatin calcium can not only lower the lipid well,but also lower the blood uric acid,so atorvastatin calcium should be preferred for hyperlipidemia patients complicated with hyperuricemia.
出处 《临床医学工程》 2011年第4期548-549,共2页 Clinical Medicine & Engineering
关键词 阿托伐他汀钙 辛伐他汀 高脂血症 高尿酸血症 Atorvastatin Simvastatin Hyperlipidemia Hyperuricemia
  • 引文网络
  • 相关文献

参考文献10

二级参考文献50

  • 1李东晓,郭立新,金世鑫.高尿酸血症和2型糖尿病在代谢综合征中的作用[J].中国糖尿病杂志,2004,12(3):202-204. 被引量:59
  • 2李东晓,迟家敏.高尿酸血症与代谢综合征[J].国外医学(内分泌学分册),2004,24(6):386-388. 被引量:70
  • 3苏工,米树华,陶红,王南晔,郑虹.代谢综合征患者血尿酸水平与冠心病的关系[J].中华内分泌代谢杂志,2005,21(1):66-67. 被引量:23
  • 4杨朝霞,代东伶,沈薇.还原型谷胱甘肽对实验性大鼠非酒精性脂肪肝的疗效观察及其分子机制探讨[J].重庆医科大学学报,2005,30(6):803-807. 被引量:8
  • 5陈新谦,金有豫,汤光.新编药理学[M].15版.北京:人民卫生出版社.2005:386.
  • 6He T, Peterson TE, Holmuhamedov EL, et al. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase [J] . Arterioscler Thromb Vasc Biol, 2004, 24: 2021-2027.
  • 7Matsumura F. On the significance of the role of cellular stress response reactions in the toxic actions of dioxin [J] . Biochem Pharmacol, 2003, 66 (4) : 527-540.
  • 8Yang S, Zhu H, Li Y, et al. Mitochondrial adaptation to obesity related oxidant stress [J] . Arch Biochem Biophys, 2000, 378 (2) : 259-268.
  • 9Urbich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors [J] . Kiddy Int, 2005, 67: 1672-1676.
  • 10Gertler MM, Garn SM, Levine SA. Serum Uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med, 1951,34 : 1421-1431.

共引文献725

同被引文献51

引证文献5

二级引证文献16

;
使用帮助 返回顶部